Patients with blood tumors can benefit from a revolutionary drug based on anti-carcinogenic antibodies. They were found in a new drug, which is a kind of Trojan horse that helps patients with chemotherapy to overcome lymphoma.
Thousands of patients with blood cancer may soon benefit from a drug based on anti-cancer antibodies, which some experts call revolutionary. It reduces the risk of relapse by 25% and relieves patients from the toxic side effects of chemotherapy. Injected into the body through a dropper, this medicine uses artificial proteins that hunt for tumors in the blood and deliver chemotherapeutic components directly to cancer cells to destroy them.
Experts call this drug similar to a Trojan horse. It produces its effect not only better than all currently used traditional treatments, but also more accurately, protecting healthy cells from damage. Now this drug called Polivy is being called the most significant breakthrough in two decades in the treatment of victims of one of the most common types of blood cancer, lymphoma, who do not respond to traditional chemotherapy.
The results of an impressive clinical trial were published last week. They showed that the drug reduces the likelihood of cancer recurrence by 25% after two years. The authors of the study were hematologists from Oxford University. They note that if a patient with lymphoma has no relapses for two years, then the probability of cancer returning is rapidly decreasing.
